Early safety check: new drug combo tested in kidney and liver patients
NCT ID NCT06911320
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This early-stage study is testing a single dose of the drug combination bemnifosbuvir/ruzasvir in 28 adults. Some participants have severe kidney or liver impairment, while others are healthy. The goal is to see how the body processes the drug and whether it is safe in these groups. No treatment benefit is expected from this study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atea Study Site
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Atea Study Site
RECRUITINGTampa, Florida, 33603, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bemnifosbuvir and ruzasvir (fixed-dose combination)
What this could lead to
If successful, this study could help determine safe dosing of this drug combination for people with severe kidney or liver impairment.
What could go wrong
This is a very early Phase 1 trial with only 28 participants. It is designed to measure drug levels and safety, not to treat any disease. Results may not apply to broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.